Athenex saw the highest growth of 0.99% in patent filings and 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Athenex‘s patent filings and grants. Buy the databook here.
Athenex has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 100% filings and 100% grants. The United States(US) patent Office are among the top ten patent offices where Athenex is filings its patents. Among the top granted patent authorities, Athenex has 100% of its grants in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for Athenex
Patents related to climate change and rare diseases lead Athenex's portfolio
Athenex has the highest number of patents in climate change followed by, rare diseases. For climate change no patents were filed and 67% of patents were granted in Q2 2024.
Stem cell transplantation related patents lead Athenex portfolio followed by viral infections, and hepacivirus infections
Athenex has highest number of patents in stem cell transplantation followed by viral infections, hepacivirus infections, hepatitis b, and kaposi sarcoma.
For comprehensive analysis of Athenex's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.